Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial
1. Blarcamesine shows unprecedented cognitive stabilization in early Alzheimer’s patients. 2. 84.7% reduction in decline on the ADAS-Cog13 cognitive test versus placebo. 3. Potential treatment for ~70% of early Alzheimer's patients identified. 4. Precision Medicine approach enhances treatment outcomes and patient accessibility. 5. Blarcamesine targets upstream mechanisms addressing Alzheimer’s, shifting treatment paradigms.